Costa Saroukos, Takeda CFO (Takeda)

Pay­ing down more debt, Take­da of­floads pre­scrip­tion drug port­fo­lio for $562 mil­lion

It’s been two years since Take­da’s $62 bil­lion Shire buy­out, and the Tokyo biotech is still re­struc­tur­ing.

The com­pa­ny struck a deal with Ger­many …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.